POMC and congenital adrenal hyperplasia: A phase Ib study including 8 women with classic CAH showed that the CRF1R antagonist NBI-77860 can effectively decrease the early morning rise of ACTH and 17-hydroxyprogesterone, eliminating the need for supraphysiologic doses of glucocorticoids (82).